Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Rebold

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 9, 2022
Panacea or oversimplification: Relating AUC and troughsNicholas Rebold, Thomas Lodise, Michael J Rybak
Pharmacotherapy|February 2, 2023
Oral stepdown in Gram-positive bloodstream infections: A step in the right directionKaylee E Caniff, Nicholas Rebold, Michael J Rybak
Infectious Diseases and Therapy|January 26, 2021
COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment OptionsNicholas Rebold, Dana Holger, Sara Alosaimy, et al.
Pharmacotherapy|January 25, 2024
Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLMDana J Holger, Ali Althubyani, Taylor Morrisette, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 22, 2026
Use of implementation frameworks to guide development and adoption of a nephrotoxin stewardship service in high-risk hospitalized patientsDhakrit Rungkitwattanakul, Nicholas Rebold, Sanaa Belrhiti, et al.
Infectious Diseases and Therapy|February 12, 2022
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosaAshlan J Kunz Coyne, Amer El Ghali, Dana Holger, et al.
Open Forum Infectious Diseases|March 27, 2023
High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase ProductionAshlan J Kunz Coyne, Amer El Ghali, Kristen Lucas, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 14, 2026
Optimizing discharge antibiotic prescribing: A multicenter evaluation of pharmacist-led interventions in community hospitalsKaylee E Caniff, Nicholas Rebold, Nathan Richards, et al.
Microbiology Spectrum|January 9, 2023
Risk Factors for Carbapenem-Resistant <i>Enterobacterales</i> Clinical Treatment FailureNicholas Rebold, Abdalhamid M Lagnf, Sara Alosaimy, et al.
Infectious Diseases and Therapy|May 10, 2022
Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19Nicholas Rebold, Sara Alosaimy, Taylor Morrisette, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 9, 2022
Panacea or oversimplification: Relating AUC and troughsNicholas Rebold, Thomas Lodise, Michael J Rybak
Pharmacotherapy|February 2, 2023
Oral stepdown in Gram-positive bloodstream infections: A step in the right directionKaylee E Caniff, Nicholas Rebold, Michael J Rybak
Infectious Diseases and Therapy|January 26, 2021
COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment OptionsNicholas Rebold, Dana Holger, Sara Alosaimy, et al.
Pharmacotherapy|January 25, 2024
Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLMDana J Holger, Ali Althubyani, Taylor Morrisette, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 22, 2026
Use of implementation frameworks to guide development and adoption of a nephrotoxin stewardship service in high-risk hospitalized patientsDhakrit Rungkitwattanakul, Nicholas Rebold, Sanaa Belrhiti, et al.
Infectious Diseases and Therapy|February 12, 2022
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosaAshlan J Kunz Coyne, Amer El Ghali, Dana Holger, et al.
Open Forum Infectious Diseases|March 27, 2023
High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase ProductionAshlan J Kunz Coyne, Amer El Ghali, Kristen Lucas, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 14, 2026
Optimizing discharge antibiotic prescribing: A multicenter evaluation of pharmacist-led interventions in community hospitalsKaylee E Caniff, Nicholas Rebold, Nathan Richards, et al.
Microbiology Spectrum|January 9, 2023
Risk Factors for Carbapenem-Resistant <i>Enterobacterales</i> Clinical Treatment FailureNicholas Rebold, Abdalhamid M Lagnf, Sara Alosaimy, et al.
Infectious Diseases and Therapy|May 10, 2022
Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19Nicholas Rebold, Sara Alosaimy, Taylor Morrisette, et al.
Pageof 2